<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36854931</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1590-3478</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology</Title><ISOAbbreviation>Neurol Sci</ISOAbbreviation></Journal><ArticleTitle>Nusinersen for adults with spinal muscular atrophy.</ArticleTitle><Pagination><StartPage>2393</StartPage><EndPage>2400</EndPage><MedlinePgn>2393-2400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10072-023-06698-9</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Nusinersen was effective in improving motor function and survival in infantile and childhood-onset spinal muscular atrophy (SMA), and the value of real-world experiences in adult SMA patients increase gradually. Here, we present our clinical experience in adult SMA patients treated with nusinersen according to CHERISH study.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Thirty-two SMA patients treated with nusinersen were included in the study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Median age at nusinersen initiation was 33.5 (20.0-60.0) years and 23 of SMA patients were male. Six (18.8%) patients had SMA type 2, and 26 (81.2%) had SMA type 3. Median follow-up period of patients under nusinersen treatment was 17 months (9-21). Twenty-three patients improved by at least 3 Hammersmith Functional Motor Scale Expanded (HFMSE) points after loading doses. There was significant HFMSE score increase in type 3 patients at each time point, whereas type 2 patients seem to benefit from nusinersen loading doses, subsequently stayed stable. Motor improvement was positively correlated with baseline HFMSE scores in patients whose baseline HFMSE scores were &#x2264;47. There was a correlation between the changes in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score and HFMSE scores. Ambulatory patients who could not show clinically meaningful increase in HFMSE scores improved at least 30 m by 6-min walk test (6MWT).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, 78% of patients have responded to treatment according to HFMSE or 6MWT. ALSFRS-R and 6MWT may be alternative tools to monitor nusinersen effect.</AbstractText><CopyrightInformation>&#xa9; 2023. Fondazione Societ&#xe0; Italiana di Neurologia.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Arslan</LastName><ForeName>Doruk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inan</LastName><ForeName>Berin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kilinc</LastName><ForeName>Muhammed</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Faculty of Physical Therapy and Rehabilitation, Hacettepe University, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bekircan-Kurt</LastName><ForeName>Can Ebru</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0003-2355-6979</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Research Laboratory, Hacettepe University, Sihhiye, 06100, Ankara, Turkey. canebru@yahoo.co.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdem-Ozdamar</LastName><ForeName>Sevim</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Research Laboratory, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Ersin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology, Neuromuscular Diseases Research Laboratory, Hacettepe University, Sihhiye, 06100, Ankara, Turkey.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Neurol Sci</MedlineTA><NlmUniqueID>100959175</NlmUniqueID><ISSNLinking>1590-1874</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Z9SP3X666</RegistryNumber><NameOfSubstance UI="C000590926">nusinersen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009134" MajorTopicYN="Y">Muscular Atrophy, Spinal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014897" MajorTopicYN="Y">Spinal Muscular Atrophies of Childhood</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adults</Keyword><Keyword MajorTopicYN="N">Hammersmith Functional Motor Scale Expanded (HFMSE)</Keyword><Keyword MajorTopicYN="N">Nusinersen</Keyword><Keyword MajorTopicYN="N">Spinal muscular atrophy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36854931</ArticleId><ArticleId IdType="doi">10.1007/s10072-023-06698-9</ArticleId><ArticleId IdType="pii">10.1007/s10072-023-06698-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Werdnig G (1971) Two early infantile hereditary cases of progressive muscular atrophy simulating dystrophy, but on a neural basis. 1891. Arch Neurol 25:276&#x2013;278. https://doi.org/10.1001/archneur.1971.00490030102014</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1971.00490030102014</ArticleId><ArticleId IdType="pubmed">4952838</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzustowicz LM, Lehner T, Castilla LH, Penchaszadeh GK, Wilhelmsen KC, Daniels R, Davies KE, Leppert M, Ziter F, Wood D, Dubowitz V, Zerres K, Hausmanowa-Petrusewicz I, Ott J, Munsat TL, Gilliam TC (1990) Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q1 1.2&#x2013;13.3. Nature 344:540&#x2013;541. https://doi.org/10.1038/344540a0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/344540a0</ArticleId><ArticleId IdType="pubmed">2320125</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefebvre S, B&#xfc;rglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155&#x2013;165. https://doi.org/10.1016/0092-8674(95)90460-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90460-3</ArticleId><ArticleId IdType="pubmed">7813012</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitte J, Fassier C, Tiziano FD, Dalard C, Soave S, Roblot N, Brahe C, Saugier-Veber P, Bonnefont JP, Melki J (2007) Refined characterization of the expression and stability of the SMN gene products. Am J Pathol 171:1269&#x2013;1280. https://doi.org/10.2353/ajpath.2007.070399</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070399</ArticleId><ArticleId IdType="pubmed">17717146</ArticleId><ArticleId IdType="pmc">1988876</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirth B (2000) An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 15:228&#x2013;237. https://doi.org/10.1002/(sici)1098-1004(200003)15:3%3c228::Aid-humu3%3e3.0.Co;2-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(sici)1098-1004(200003)15:3&lt;228::Aid-humu3&gt;3.0.Co;2-9</ArticleId><ArticleId IdType="pubmed">10679938</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH (1998) Differential SMN2 expression associated with SMA severity. Nat Genet 20:230&#x2013;231. https://doi.org/10.1038/3030</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/3030</ArticleId><ArticleId IdType="pubmed">9806538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM (2016) Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology 86:890&#x2013;897. https://doi.org/10.1212/wnl.0000000000002445</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000002445</ArticleId><ArticleId IdType="pubmed">26865511</ArticleId><ArticleId IdType="pmc">4782111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF, Krainer AR (2010) Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 24:1634&#x2013;1644. https://doi.org/10.1101/gad.1941310</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1941310</ArticleId><ArticleId IdType="pubmed">20624852</ArticleId><ArticleId IdType="pmc">2912561</ArticleId></ArticleIdList></Reference><Reference><Citation>Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3:72ra18. https://doi.org/10.1126/scitranslmed.3001777</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.3001777</ArticleId><ArticleId IdType="pubmed">21368223</ArticleId><ArticleId IdType="pmc">3140425</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS (2018) Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 378:625&#x2013;635. https://doi.org/10.1056/NEJMoa1710504</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1710504</ArticleId><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Glanzman AM, O&#x2019;Hagen JM, McDermott MP, Martens WB, Flickinger J, Riley S, Quigley J, Montes J, Dunaway S, Deng L, Chung WK, Tawil R, Darras BT, De Vivo DC, Kaufmann P, Finkel RS (2011) Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III. J Child Neurol 26:1499&#x2013;1507. https://doi.org/10.1177/0883073811420294</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0883073811420294</ArticleId><ArticleId IdType="pubmed">21940700</ArticleId></ArticleIdList></Reference><Reference><Citation>Kleyweg RP, van der Mech&#xe9; FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr&#xe9; syndrome. Muscle Nerve 14:1103&#x2013;1109. https://doi.org/10.1002/mus.880141111</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880141111</ArticleId><ArticleId IdType="pubmed">1745285</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13&#x2013;21. https://doi.org/10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes J, McDermott MP, Martens WB, Dunaway S, Glanzman AM, Riley S, Quigley J, Montgomery MJ, Sproule D, Tawil R, Chung WK, Darras BT, De Vivo DC, Kaufmann P, Finkel RS (2010) Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology 74:833&#x2013;838. https://doi.org/10.1212/WNL.0b013e3181d3e308</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181d3e308</ArticleId><ArticleId IdType="pubmed">20211907</ArticleId><ArticleId IdType="pmc">2839195</ArticleId></ArticleIdList></Reference><Reference><Citation>Pera MC, Coratti G, Forcina N, Mazzone ES, Scoto M, Montes J, Pasternak A, Mayhew A, Messina S, Sframeli M, Main M, Lofra RM, Duong T, Ramsey D, Dunaway S, Salazar R, Fanelli L, Civitello M, de Sanctis R, Antonaci L, Lapenta L, Lucibello S, Pane M, Day J, Darras BT, De Vivo DC, Muntoni F, Finkel R, Mercuri E (2017) Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy. BMC Neurol 17:39. https://doi.org/10.1186/s12883-017-0790-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-017-0790-9</ArticleId><ArticleId IdType="pubmed">28231823</ArticleId><ArticleId IdType="pmc">5324197</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunaway Young S, Montes J, Kramer SS, Marra J, Salazar R, Cruz R, Chiriboga CA, Garber CE, De Vivo DC (2016) Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54:836&#x2013;842. https://doi.org/10.1002/mus.25120</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25120</ArticleId><ArticleId IdType="pubmed">27015431</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung G, Schneider E, Norris DA, Xia S, Bennett CF, Bishop KM (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017&#x2013;3026. https://doi.org/10.1016/s0140-6736(16)31408-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(16)31408-8</ArticleId><ArticleId IdType="pubmed">27939059</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723&#x2013;1732. https://doi.org/10.1056/NEJMoa1702752</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1702752</ArticleId><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, Ramsey D, Mayhew A, Glanzman AM, Dunaway S, Salazar R, Pasternak A, Quigley J, Pane M, Pera MC, Scoto M, Messina S, Sframeli M, Vita GL, D&#x2019;Amico A, van den Hauwe M, Sivo S, Goemans N, Kaufmann P, Darras BT, Bertini E, Muntoni F, De Vivo DC (2016) Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord 26:126&#x2013;131. https://doi.org/10.1016/j.nmd.2015.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2015.10.006</ArticleId><ArticleId IdType="pubmed">26776503</ArticleId><ArticleId IdType="pmc">4762230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Sansone V (2020) Nusinersen in adults with spinal muscular atrophy: new challenges. Lancet Neurol 19:283&#x2013;284. https://doi.org/10.1016/s1474-4422(20)30068-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30068-5</ArticleId><ArticleId IdType="pubmed">32199087</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, Kirschner J, Iannaccone ST, Crawford TO, Woods S, Muntoni F, Wirth B, Montes J, Main M, Mazzone ES, Vitale M, Snyder B, Quijano-Roy S, Bertini E, Davis RH, Qian Y, Sejersen T (2018) Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord 28:197&#x2013;207. https://doi.org/10.1016/j.nmd.2017.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nmd.2017.11.004</ArticleId><ArticleId IdType="pubmed">29305137</ArticleId></ArticleIdList></Reference><Reference><Citation>Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, Stahl K, Pechmann A, Lochm&#xfc;ller H, Kirschner J, Schoser B (2019) Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 &#x2014; a prospective observational study. J Neuromuscul Dis 6:453&#x2013;465. https://doi.org/10.3233/jnd-190416</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jnd-190416</ArticleId><ArticleId IdType="pubmed">31594243</ArticleId><ArticleId IdType="pmc">6918909</ArticleId></ArticleIdList></Reference><Reference><Citation>Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, Ciafaloni E (2020) Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve 61:222&#x2013;226. https://doi.org/10.1002/mus.26769</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26769</ArticleId><ArticleId IdType="pubmed">31773738</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochmann E, Steinbach R, Jochmann T, Chung HY, R&#xf6;diger A, Neumann R, Mayer TE, Kirchhof K, Loudovici-Krug D, Smolenski UC, Witte OW, Grosskreutz J (2020) Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. Ther Adv Neurol Disord 13:1756286420907803. https://doi.org/10.1177/1756286420907803</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756286420907803</ArticleId><ArticleId IdType="pubmed">32180828</ArticleId><ArticleId IdType="pmc">7059230</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagenacker T, Wurster CD, G&#xfc;nther R, Schreiber-Katz O, Osmanovic A, Petri S, Weiler M, Ziegler A, Kuttler J, Koch JC, Schneider I, Wunderlich G, Schloss N, Lehmann HC, Cordts I, Deschauer M, Lingor P, Kamm C, Stolte B, Pietruck L, Totzeck A, Kizina K, M&#xf6;nninghoff C, von Velsen O, Ose C, Reichmann H, Forsting M, Pechmann A, Kirschner J, Ludolph AC, Hermann A, Kleinschnitz C (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol 19:317&#x2013;325. https://doi.org/10.1016/s1474-4422(20)30037-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1474-4422(20)30037-5</ArticleId><ArticleId IdType="pubmed">32199097</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ (2020) Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis 7:257&#x2013;268. https://doi.org/10.3233/jnd-190453</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jnd-190453</ArticleId><ArticleId IdType="pubmed">32333595</ArticleId></ArticleIdList></Reference><Reference><Citation>Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, Grandis M, Trojsi F, Cerri F, Ferraro M, Bozzoni V, Caumo L, Piras R, Tanel R, Saccani E, Meneri M, Vacchiano V, Ricci G, Soraru G, D&#x2019;Errico E, Tramacere I, Bortolani S, Pavesi G, Zanin R, Silvestrini M, Politano L, Schenone A, Previtali SC, Berardinelli A, Turri M, Verriello L, Coccia M, Mantegazza R, Liguori R, Filosto M, Marrosu G, Siciliano G, Simone IL, Mongini T, Comi G, Pegoraro E (2020) Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 91:1166&#x2013;1174. https://doi.org/10.1136/jnnp-2020-323822</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323822</ArticleId><ArticleId IdType="pubmed">32917822</ArticleId></ArticleIdList></Reference><Reference><Citation>Coratti G, Cutrona C, Pera MC, Bovis F, Ponzano M, Chieppa F, Antonaci L, Sansone V, Finkel R, Pane M, Mercuri E (2021) Motor function in type 2 and 3 SMA patients treated with nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis 16:430. https://doi.org/10.1186/s13023-021-02065-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-021-02065-z</ArticleId><ArticleId IdType="pubmed">34645478</ArticleId><ArticleId IdType="pmc">8515709</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wel B, Goosens V, Sobota A, Van Camp E, Geukens E, Van Kerschaver G, Jagut M, Claes K, Claeys KG (2021) Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol 268:923&#x2013;935. https://doi.org/10.1007/s00415-020-10223-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10223-9</ArticleId><ArticleId IdType="pubmed">32935160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>